HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NSF standard for organic products

This article was originally published in The Rose Sheet

Executive Summary

The National Standards Foundation is accepting comments on its draft standard for organic personal-care products. The proposed standard consists of requirements for the labeling and marketing of organic personal-care products, as well as specifications for processes, production and agricultural and synthetic ingredients. The regulations cover leave-on and wash-off personal care and cosmetic products as well as oral care and personal hygiene items. To date, manufacturers seeking U.S. organic certification for their personal-care offerings have had to appeal to the USDA standards for food. Comments on the draft standards can be submitted on the NSF Web site; they will be accepted until March 3. The task force charged by NSF to develop the standards first met in early 2007 (1"The Rose Sheet" Jan. 29, 2007, p. 5)...

You may also be interested in...



Task Force To Release Standards For Organic Personal Care Products In 2007

A task force of industry reps and consumer advocates will release the first draft of standards for organic personal care products by mid-2007, insiders say

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS015205

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel